Clinical Trial Update: RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of RAD001 and CP-751,871 in patients with advanced sarcomas and other malignant neoplasms has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma
• Solid Tumor

Drugs mentioned

• CP-751,871 (dalotuzumab)
• RAD001 (everolimus)

Snippet

Sponsor: Suzanne George, MD | Conditions: Sarcoma, Solid Tumor | Phase 1 | Status: COMPLETED